Ocugen Advances Gene Therapy Pipeline, Targets OCU400 Approval in 2027
OCGN has more than doubled off its 52-week low of $0.515.
Summary
Ocugen delivered a comprehensive business update, detailing significant progress across its gene therapy pipeline for blindness diseases. Key highlights include the completion of Phase 3 enrollment for OCU400, with topline data anticipated in Q1 2027 and potential FDA approval in 2027. The company also reported that its OCU410ST Phase 2/3 trial is nearing enrollment completion, with interim data expected in Q3 2026. Additionally, Ocugen announced a regional licensing agreement for OCU400, marking the start of its commercialization strategy. While the accompanying Q4 and full-year 2025 financial results were largely anticipated and previously reported, these pipeline advancements and strategic developments provide crucial forward-looking catalysts for the company. Traders will closely watch the upcoming data readouts and regulatory milestones for these programs.
At the time of this announcement, OCGN was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.9M. The 52-week trading range was $0.52 to $1.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.